FindTrial
Sign In

Determination of cox2 expression in colorectal carcinoma predicts the recurrence rate after surgical resection or adjuvant therapy, the goal of this study is to assess the effectiveness of cox2 as a prognostic marker in colorectal carcinoma by using immunohistochemistry.

To study the utility of COX2 as immunohistochemical prognostic marker in comparison to various histopathological parameters and TNM staging in colorectal carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/05/052619
Enrollment
65
Registered
2023-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C189- Malignant neoplasm of colon, unspecified Health Condition 2: C189- Malignant neoplasm of colon, unspecified Health Condition 3: C189- Malignant neoplasm of colon, unspecified

Interventions

Control Intervention1: NIL: NIL Control Intervention2: NIL: NIL

Sponsors

Datta Meghe institute of Medical Science
Lead Sponsor
Sreetama Mukherjee
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.All cases diagnosed as colorectal carcinoma on histopathology. 2.All colectomy/Hemicolectomy/ Proctocolectomy resection specimens. 3.Primary cases of colorectal carcinoma without any history of previous treatment. 4.All patients presenting with colorectal carcinoma arising Denovo.

Exclusion criteria

Exclusion criteria: 1.All inflammatory lesions, and other malignancies of the gastrointestinal tract. 2.All biopsy specimens. 3.All treated cases of colorectal carcinoma and cases with recurrence

Design outcomes

Primary

MeasureTime frame
Immunohistochemical analysis in determining cox2 expression used as a prognostic marker in colorectal carcinoma in correlation with TNM staging.Timepoint: 3 YEARS—

Secondary

MeasureTime frame
It can be used to identify patients with poor clinical outcomes and those who will benefit from early diagnosis.Timepoint: 3 YEARS—

Countries

India

Contacts

Public ContactSreetama Mukherjee

JNMC.SWANGI MEGHE.WARDHA

sunitavagha@gmail.com9860244638

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026